CRVS Logo

Corvus Pharmaceuticals, Inc. (CRVS) 

NASDAQ
Market Cap
$534.5M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
106 of 776
Rank in Industry
75 of 433

Largest Insider Buys in Sector

CRVS Stock Price History Chart

CRVS Stock Performance

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of …

Insider Activity of Corvus Pharmaceuticals, Inc.

Over the last 12 months, insiders at Corvus Pharmaceuticals, Inc. have bought $1.03M and sold $0 worth of Corvus Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Corvus Pharmaceuticals, Inc. have bought $2.14M and sold $23.37M worth of stock each year.

Highest buying activity among insiders over the last 12 months: MILLER RICHARD A MD (President and CEO) — $1,000,000. Jones William Benton (See Remarks) — $34,624.

The last purchase of 577,634 shares for transaction amount of $1,000,000 was made by MILLER RICHARD A MD (President and CEO) on 2024‑05‑06.

List of Insider Buy and Sell Transactions, Corvus Pharmaceuticals, Inc.

2024-05-06PurchasePresident and CEO
577,634
1.0676%
$1.73$1,000,000+87.96%
2024-05-06PurchaseSee Remarks
20,000
0.037%
$1.73$34,624+87.96%
2023-05-15Purchasedirector
10,000
0.0202%
$2.45$24,500-23.08%
2022-12-20PurchaseSee Remarks
20,000
0.0435%
$0.79$15,800+85.90%
2022-12-14PurchasePresident and CEO
10,000
0.021%
$0.78$7,812+78.13%
2022-12-14PurchaseChief Financial Officer
4,000
0.009%
$0.84$3,364+78.13%
2022-12-13PurchasePresident and CEO
50,000
0.1031%
$0.74$37,015+84.18%
2022-12-13PurchaseChief Financial Officer
30,000
0.0621%
$0.74$22,275+84.18%
2022-06-24PurchasePresident and CEO
5,000
0.0123%
$1.00$4,985+4.60%
2022-06-02PurchasePresident and CEO
890
0.002%
$1.01$899-7.89%
2022-03-31PurchasePresident and CEO
15,000
0.0321%
$1.64$24,534-44.51%
2022-03-16PurchaseChief Financial Officer
13,878
0.0307%
$1.65$22,899-42.38%
2022-03-15PurchasePresident and CEO
5,000
0.0117%
$1.59$7,950-36.44%
2021-10-01Sale10 percent owner
2M
4.4342%
$4.96$9.93M-67.36%
2021-09-30Sale10 percent owner
3M
6.7156%
$5.04$15.13M-67.46%
2021-09-20Sale
1.11M
2.4922%
$6.09$6.76M-73.58%
2021-09-20Sale
1.11M
2.4922%
$6.09$6.76M-73.58%
2021-08-20PurchasePresident and CEO
10,000
0.0229%
$1.93$19,254-5.76%
2021-05-04PurchasePresident and CEO
35,714
0.0833%
$2.80$99,999-13.38%
2021-02-17Purchase
1.29M
3.6216%
$3.50$4.5M-23.75%

Insider Historical Profitability

6.75%
MILLER RICHARD A MDPresident and CEO
577634
0.9235%
$8.55290+5.51%
Jones William BentonSee Remarks
153773
0.2458%
$8.5520+85.9%
ORBIMED ADVISORS LLC
6943654
11.1007%
$8.55191+4.76%
Thompson Peter A.
6943654
11.1007%
$8.55191+4.76%
Novo Holdings A/S10 percent owner
1389498
2.2214%
$8.5535+12.06%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$12.36M11.16.94M0%+$00.1
Adams Street Partners Llc$5.83M5.243.28M0%+$02.32
Samlyn Capital, LLC$4.18M3.752.35M-5.92%-$263,254.870.07
The Vanguard Group$2.66M2.391.49M+10.57%+$254,048.68<0.0001
Renaissance Technologies$1.13M1.02637,032+8.44%+$88,294.47<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.